title: Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients.
authors.affiliation: Department of Clinical Research, Boehringer Mannheim GmbH, FRG.
authors.forename: P
authors.initials: P
authors.lastname: Scigalla
authors.forename: D
authors.initials: D
authors.lastname: Messinger
authors.forename: L
authors.initials: L
authors.lastname: Wieczorek
mesh_terms: D000328:Adult; D000535:Aluminum / Q000633:toxicity; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000747:Anemia, Hypochromic / Q000150:complications / Q000628:therapy; D004920:Erythropoiesis / Q000502:physiology; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology; D007239:Infections / Q000150:complications; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008875:Middle Aged; D009780:Occult Blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D000535:Aluminum